Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A01786 | 34618619 | Scand J Gastroenterol | Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. | 2021 | Details |
| A01787 | 34618611 | Immunopharmacol Immunotoxicol | Capillin protects against non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation and oxidative stress. | 2021 | Details |
| A01793 | 34615727 | Gut | Novel therapeutic targets for cholestatic and fatty liver disease. | 2021 | Details |
| A01795 | 34613814 | Sci Transl Med | Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis. | 2021 | Details |
| A01799 | 34610926 | BMJ Open Gastroenterol | Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. | 2021 | Details |
| A01800 | 34610720 | Diabetes Metab J | Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases. | 2021 | Details |
| A01805 | 34609086 | United European Gastroenterol J | Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease. | 2021 | Details |
| A01806 | 34608587 | Hepatol Int | Hepatic fibrosis is associated with an increased rate of decline in bone mineral density in men with nonalcoholic fatty liver disease. | 2021 | Details |
| A01809 | 34607067 | Clin Res Hepatol Gastroenterol | Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis. | 2021 | Details |
| A01811 | 34606980 | Endocr Pract | Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. | 2021 | Details |
| A01813 | 34606912 | J Hepatol | Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it? | 2021 | Details |
| A01815 | 34606548 | Food Funct | Sesamol supplementation alleviates nonalcoholic steatohepatitis and atherosclerosis in high-fat, high carbohydrate and high-cholesterol diet-fed rats. | 2021 | Details |
| A01829 | 34602251 | Gastroenterology | Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01835 | 34600973 | J Hepatol | ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. | 2021 | Details |
| A01837 | 34599938 | Life Sci | Curcumin activation of nuclear factor E2-related factor 2 gene (Nrf2): Prophylactic and therapeutic effect in nonalcoholic steatohepatitis (NASH). | 2021 | Details |
| A01839 | 34597608 | Life Sci | The role of Sirtuin 2 in sustaining functional integrity of the liver. | 2021 | Details |
| A01843 | 34593018 | BMC Pharmacol Toxicol | Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis. | 2021 | Details |
| A01844 | 34592488 | Phytomedicine | Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis. | 2021 | Details |
| A01845 | 34592210 | Chemosphere | Blood manganese and nonalcoholic fatty liver disease: A cohort-based case-control study. | 2021 | Details |
| A01846 | 34591986 | Hepatology | OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways. | 2021 | Details |
| A01850 | 34590082 | Aust J Gen Pract | Updates in fatty liver disease: Pathophysiology, diagnosis and management. | 2021 | Details |
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | 2021 | Details |
| A01854 | 34588551 | Sci Rep | Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis. | 2021 | Details |
| A01855 | 34588540 | Sci Rep | Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease. | 2021 | Details |
| A01864 | 34583706 | Cardiovasc Diabetol | The association of hepatic steatosis and fibrosis with heart failure and mortality. | 2021 | Details |
| A01865 | 34583137 | Nutrition | Impedance-based measures of muscle mass can be used to predict severity of hepatic steatosis in pediatric nonalcoholic fatty liver disease. | 2021 | Details |
| A01868 | 34579068 | Nutrients | The Effect of Probiotics (MCP® BCMC® Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A01871 | 34578919 | Nutrients | Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. | 2021 | Details |
| A01873 | 34578828 | Nutrients | Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD. | 2021 | Details |
| A01876 | 34576136 | Int J Mol Sci | Sex Dimorphism of Nonalcoholic Fatty Liver Disease (NAFLD) in Pparg-Null Mice. | 2021 | Details |
| A01883 | 34573947 | Diagnostics (Basel) | Determining the Target Population That Would Most Benefit from Screening for Hepatic Fibrosis in a Primary Care Setting. | 2021 | Details |
| A01886 | 34572795 | Cancers (Basel) | Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01888 | 34572434 | Biomedicines | Clinical Significance of HSPD1/MMP14/ITGB1/miR-6881-5P/Lnc-SPARCL1-1:2 RNA Panel in NAFLD/NASH Diagnosis: Egyptian Pilot Study. | 2021 | Details |
| A01895 | 34570568 | Bratisl Lek Listy | Serum butyrylcholinesterase activities in patients with non-alcoholic fatty liver disease. Comparison with liver proteosynthetic function and liver fibrosis. | 2021 | Details |
| A01899 | 34567270 | Therap Adv Gastroenterol | Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey. | 2021 | Details |
| A01912 | 34564899 | J Intern Med | Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. | 2021 | Details |
| A01918 | 34563519 | J Lipid Res | Inhibition of chylomicron assembly leads to dissociation of hepatic steatosis from inflammation and fibrosis. | 2021 | Details |
| A01922 | 34560854 | Cardiovasc Diabetol | Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study. | 2021 | Details |
| A01931 | 34558856 | Hepatol Commun | Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. | 2021 | Details |
| A01933 | 34558853 | Hepatol Commun | Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. | 2021 | Details |
| A01934 | 34558849 | Hepatol Commun | Distinct Hepatic Gene-Expression Patterns of NAFLD in Patients With Obesity. | 2021 | Details |
| A01937 | 34558835 | Hepatol Commun | Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. | 2021 | Details |
| A01938 | 34558829 | Hepatol Commun | Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. | 2021 | Details |
| A01939 | 34558828 | Hepatol Commun | PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD. | 2021 | Details |
| A01943 | 34557660 | JHEP Rep | Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. | 2021 | Details |
| A01953 | 34555346 | Lancet Gastroenterol Hepatol | Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. | 2021 | Details |
| A01955 | 34555255 | Liver Int | COVID-19, adaptative immune response and metabolic-associated liver disease. | 2021 | Details |
| A01956 | 34554611 | J Paediatr Child Health | Liver stiffness measurement as a quantitative method for liver fibrosis in children with non-alcoholic fatty liver disease: A meta-analysis. | 2021 | Details |
| A01957 | 34553836 | Obesity (Silver Spring) | Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. | 2021 | Details |
| A01962 | 34551612 | Future Med Chem | Xanthohumol alleviates T2DM-induced liver steatosis and fibrosis by mediating the NRF2/RAGE/NF-κB signaling pathway. | 2021 | Details |
| A01967 | 34549325 | Eur Radiol | Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis. | 2021 | Details |
| A01969 | 34548598 | Sci Rep | Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis. | 2021 | Details |
| A01973 | 34546515 | Obes Surg | Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease. | 2021 | Details |
| A01976 | 34544714 | BMJ Case Rep | Hepatopulmonary syndrome as the first and only manifestation of cirrhosis in a patient with hypopituitarism. | 2021 | Details |
| A01977 | 34543756 | Clin Res Hepatol Gastroenterol | Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19. | 2021 | Details |
| A01978 | 34543735 | Diabetes Metab | Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design. | 2021 | Details |
| A01979 | 34543610 | Lancet | Liver cirrhosis. | 2021 | Details |
| A01986 | 34540943 | Visc Med | Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). | 2021 | Details |
| A01988 | 34537988 | Hepatology | Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. | 2021 | Details |
| A01994 | 34536163 | J Med Ultrason (2001) | Quantitative assessment of liver steatosis using ultrasound: dual-energy CT. | 2021 | Details |
| A01997 | 34535562 | J Pharmacol Exp Ther | Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model. | 2021 | Details |
| A01998 | 34534913 | Redox Biol | Hepatic Regulator of G Protein Signaling 6 (RGS6) drives non-alcoholic fatty liver disease by promoting oxidative stress and ATM-dependent cell death. | 2021 | Details |
| A02002 | 34533632 | J Gastroenterol | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. | 2021 | Details |
| A02003 | 34533606 | Eur Radiol | Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD. | 2021 | Details |
| A02004 | 34533266 | Hepatol Res | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. | 2021 | Details |
| A02007 | 34532996 | Hepatol Commun | TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease. | 2021 | Details |
| A02012 | 34531129 | Dig Liver Dis | Troglitazone inhibits hepatic oval cell proliferation by inducing cell cycle arrest through Hippo/YAP pathway regulation. | 2021 | Details |
| A02013 | 34530928 | Microbiome | Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. | 2021 | Details |
| A02020 | 34529067 | JAMA Netw Open | Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A02022 | 34528723 | Aliment Pharmacol Ther | Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A02027 | 34527094 | Gastroenterology Res | Non-Invasive Assessment of Liver Fibrosis and Steatosis in End-Stage Renal Disease Patients Undergoing Renal Transplant Evaluation. | 2021 | Details |
| A02030 | 34526653 | Commun Biol | Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. | 2021 | Details |
| A02031 | 34525916 | Curr Med Chem | Beneficial Effects of Dietary Polyphenols in the Prevention and Treatment of NAFLD: Cell-Signaling Pathways Underlying Health Effects. | 2022 | Details |
| A02041 | 34522873 | EClinicalMedicine | Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). | 2021 | Details |
| A02042 | 34522493 | Cureus | The Role of Vitamins in Non-Alcoholic Fatty Liver Disease: A Systematic Review. | 2021 | Details |
| A02047 | 34521152 | Liver Int | Higher dietary insulinaemic potential is associated with increased risk of liver steatosis and fibrosis. | 2021 | Details |
| A02052 | 34519576 | Radiology | Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study. | 2021 | Details |
| A02054 | 34519101 | Hepatology | The RNA binding protein human antigen R is a gatekeeper of liver homeostasis. | 2021 | Details |
| A02056 | 34517467 | Zhonghua Gan Zang Bing Za Zhi | [Research progress on non-alcoholic fatty liver disease animal models]. | 2021 | Details |
| A02059 | 34517014 | Metabolism | Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes. | 2021 | Details |
| A02060 | 34516703 | Int J Clin Pract | Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial. | 2021 | Details |
| A02063 | 34515137 | J Innate Immun | The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A02064 | 34513923 | Front Mol Biosci | The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis. | 2021 | Details |
| A02065 | 34513896 | Front Med (Lausanne) | The Effects of Modest Alcohol Consumption on Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2021 | Details |
| A02073 | 34511816 | J Clin Exp Hepatol | Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis. | 2020 | Details |
| A02088 | 34509679 | World Neurosurg | Thrombocytopenia Associated with Unrecognized Non-Alcoholic Fatty Liver Disease Is an Independent Predictor of Perioperative Significant Blood Loss in Cervical Laminoplasty. | 2021 | Details |
| A02090 | 34509375 | Surg Obes Relat Dis | Bariatric surgery improves metabolic and nonalcoholic fatty liver disease markers in metabolically healthy patients with morbid obesity at 5 years. | 2021 | Details |
| A02095 | 34508791 | J Hepatol | Rational HCC screening approaches for patients with NAFLD. | 2021 | Details |
| A02101 | 34508113 | Sci Rep | Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. | 2021 | Details |
| A02102 | 34507895 | Dig Liver Dis | The safety and efficacy evaluation of Sodium-Glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty Liver disease: An updated meta-analysis. | 2021 | Details |
| A02103 | 34506332 | Clin Transl Gastroenterol | The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. | 2021 | Details |
| A02105 | 34505899 | Nephrol Dial Transplant | Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study. | 2021 | Details |
| A02107 | 34505423 | Endocrinol Diabetes Metab | Oxy210, a novel inhibitor of hedgehog and TGF-β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice. | 2021 | Details |
| A02109 | 34504179 | Sci Rep | Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease. | 2021 | Details |
| A02111 | 34503201 | Cancers (Basel) | Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer. | 2021 | Details |
| A02116 | 34501508 | Int J Environ Res Public Health | Relationships of Dietary Habits and Physical Activity Status with Non-Alcoholic Fatty Liver Disease Featuring Advanced Fibrosis. | 2021 | Details |
| A02117 | 34501231 | J Clin Med | Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. | 2021 | Details |
| A02119 | 34499619 | J Clin Invest | Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD. | 2021 | Details |
| A02120 | 34499435 | Hepatol Commun | What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? | 2021 | Details |
| A02121 | 34498502 | Ann Med | High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China. | 2021 | Details |